Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024)

Tango Therapeutics (TNGX) has 6 years of Non Operating Investment Income data on record, last reported at $27000.0 in Q3 2025.

  • For Q3 2025, Non Operating Investment Income changed N/A year-over-year to $27000.0; the TTM value through Sep 2025 reached $1.3 million, changed N/A, while the annual FY2025 figure was -$112000.0, 174.67% down from the prior year.
  • Non Operating Investment Income reached $27000.0 in Q3 2025 per TNGX's latest filing, up from -$443000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $1.5 million in Q1 2023 and bottomed at -$2.6 million in Q1 2022.
  • Average Non Operating Investment Income over 5 years is -$17642.9, with a median of $1500.0 recorded in 2021.
  • Peak YoY movement for Non Operating Investment Income: crashed 17733.33% in 2022, then surged 264.24% in 2023.
  • A 5-year view of Non Operating Investment Income shows it stood at -$755000.0 in 2021, then skyrocketed by 252.45% to $1.2 million in 2022, then dropped by 24.67% to $867000.0 in 2023, then crashed by 151.1% to -$443000.0 in 2024, then skyrocketed by 106.09% to $27000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Investment Income were $27000.0 in Q3 2025, -$443000.0 in Q1 2024, and $867000.0 in Q4 2023.